Mineralys Therapeutics Change in Accounts Payable 2021-2025 | MLYS

Mineralys Therapeutics change in accounts payable from 2021 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

Mineralys Therapeutics Change in Accounts Payable 2021-2025 | MLYS

Mineralys Therapeutics change in accounts payable from 2021 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$213.3B
Amgen (AMGN)$158.5B
Gilead Sciences (GILD)$134.6B
Vertex Pharmaceuticals (VRTX)$118.1B
Bristol Myers Squibb (BMY)$96.4B
CSL (CSLLY)$81.2B
GSK (GSK)$74.3B
Regeneron Pharmaceuticals (REGN)$58.6B
Alnylam Pharmaceuticals (ALNY)$41.8B
Argenex SE (ARGX)$34.6B
BioNTech SE (BNTX)$26.4B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.3B
Illumina (ILMN)$15.2B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$14B
Incyte (INCY)$13.1B
Exelixis (EXEL)$12.1B
Moderna (MRNA)$12.1B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.4B
Exact Sciences (EXAS)$9.5B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.2B
Roivant Sciences (ROIV)$7.8B
Legend Biotech (LEGN)$7.6B